GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas GSK is the largest ...

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The update includes ...

(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Wednesday its plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. (“Bora”; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and GSK (LSE/NYSE: GSK) have signed a ...